Rockwell Medical, Inc.RMTI

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$8.57
Market cap
$34.5M
P/E
—
Revenue (TTM)
$69.4M
Net income
-$5.1M
Dividend yield
—
1-year total return
-29.8%
Net margin
-7.3%
Revenue growth
-21.1%
Debt / equity
0.26x

What Rockwell Medical, Inc. does.

Unless otherwise indicated in this Annual Report on Form 10-K “we,” “our,” “us,” “the Company,” "Rockwell," “Rockwell Medical,” and other similar terms refer to Rockwell Medical, Inc., together with its consolidated subsidiaries. You are advised to read this Annual Report on Form 10-K in conjunction with other reports and documents that we file from time to time with the Securities and Exchange Commission (“SEC”). In particular, please read our definitive proxy statement, which will be filed with the SEC in connection with our 2026 annual meeting of stockholders, our quarterly reports on Form 10-Q and any current reports on Form 8-K that we may file from time to time. You can access free of charge on our website copies of these reports as soon as practicable after they are electronically filed with the SEC. The SEC also maintains a website on the internet that contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC.

CitraPure ® , Dri-Sate ® , RenalPure ® , and SteriLyte ® are registered trademarks of Rockwell Medical. This Annual Report on Form 10-K contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$62.2M$61.9M$72.8M$83.6M$101.5M$69.3M
Net income-$30.9M-$32.7M-$18.7M-$8.4M-$480,000-$5.3M
Free cash flow———-$9.7M$3.2M-$1.2M

More on RMTI.

Figures from Rockwell Medical, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.